© Reuters.
BOSTON and ROLLE, Switzerland – SOPHiA GENETICS (NASDAQ: SOPH), a pacesetter in data-driven drugs, has introduced a partnership with Karkinos Healthcare to boost most cancers analysis and care in India. This collaboration goals to offer superior genomic options and enhance customized therapy for blood cancers and stable tumors, notably in rural and underserved communities.
Karkinos Healthcare, an oncology platform centered on early detection, diagnostics, and therapy, is ready to undertake the SOPHiA DDM
Platform. This expertise is anticipated to bolster their capabilities in addressing the accessibility and affordability gaps in most cancers care via their ‘Neighborhood as a Most cancers Centre’ initiative.
Dr. Jurgi Camblong, CEO and Co-founder of SOPHiA GENETICS, emphasised the shared purpose with Karkinos to develop entry to precision oncology and equip native well being establishments with mandatory instruments for data-driven drugs. The SOPHiA DDM Platform will allow Karkinos Healthcare to advance analysis and streamline workflow for numerous cancers, together with Myeloid and Lymphoma, in addition to stable tumors like ovarian, prostate, and breast cancers.
Dr. R Venkataramanan, Founder and CEO of Karkinos Healthcare, highlighted the partnership’s potential to generate world-class analysis for quicker and extra correct most cancers prognosis and administration, with a give attention to precision drugs for the underprivileged in India.
The SOPHiA DDM Platform provides tailor-made next-generation sequencing (NGS) workflows to speed up evaluation from pattern to report, facilitating speedy, high-quality information acquisition for scientific analysis research.
This strategic alliance is a part of SOPHiA GENETICS’ broader mission to make data-driven drugs a normal of care globally. The corporate’s expertise is already in use by a large community of hospitals, laboratories, and biopharma establishments all over the world.
Karkinos Healthcare, supported by distinguished buyers together with the Tata Group and Reliance Industries, operates with a imaginative and prescient to offer complete most cancers care nearer to sufferers’ houses, leveraging a distributed most cancers care community and partnerships with main healthcare establishments.
This press launch assertion signifies the forward-looking nature of the partnership, with the caveat that precise outcomes might differ from expectations attributable to numerous elements.
This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.
The put up SOPHiA GENETICS joins with Karkinos for cancer care in India By Investing.com first appeared on Investorempires.com.
